New technology to enhance therapeutic potential of cord blood stem cellsJune 7th, 2008 - 5:31 pm ICT by ANI
Washington, June 7 (ANI): Researchers from Rush University Medical Centre have found a new method to enhance and expand homing and therapeutic potential of cord blood stem cells in bone marrow transplants.
The new technique, known as CD26 Inhibitor, can increase the efficiency and responsiveness of umbilical cord blood for bone marrow transplants and may improve care for blood cancer patients.
CD26 Inhibitor is a small molecule enzyme inhibitor that enhances directional homing of stem cells to the bone marrow by increasing the responsiveness of donor stem cells to a natural homing signal.
Homing is the process by which the donor stem cells find their way to the bone marrow. It is the first and essential step in stem cell transplantation.
The studies conducted on animal models by Kent W. Christopherson II, PhD, assistant professor of medicine and researcher in the Sections of Hematology and Stem Cell Transplantation and Dr. Patrick Zweidler-McKay of the University if Texas MD Anderson Cancer Centre showed that both Engraftin, a human recombinant enzyme technology that increases the efficiency of engraftment and reduces graft failure in transplantation of cord blood derived stem cells and CD26 Inhibitor can enhance homing and rate of engraftment, which will result in reduced patient morbidity and mortality in bone marrow transplants.
Cord blood is being increasingly used by transplant centres as an alternative source of stem cells for the treatment of blood cancers, including myeloma, lymphoma and leukemia.
The cells, which are collected from the umbilical cord after the baby is delivered and separated from the cord, are most commonly used for bone marrow transplantation when a donor from a patients family or an unrelated donor does not produce an appropriate bone marrow match.
The current drawback to the usage of cord blood cells is that due to the limited volume and cell number, there are generally only enough cells available from a single cord blood collection for children or very small adults.
Cord blood cells also usually take longer to engraft, leaving the patient at a high risk for infection longer than donor matched transplanted marrow or peripheral blood stem cells
Christopherson is researching a CD26 Inhibitor and aims to increase the transplant efficiency of umbilical cord blood and ultimately make transplant safer and available to all patients who require this treatment. (ANI)
- Sahara Hospital to start bone-marrow transplant - Sep 24, 2011
- Turning diseased blood cells to stem cells may reveal cancer quickly - Feb 05, 2011
- Stem cell transplant cheap in India, but very few centres - Jan 01, 2011
- New 'stretchy' technique generates 3 times more stem cells than usual - Oct 04, 2010
- Iraqi woman gets new life with bone marrow transplant in India - Sep 23, 2010
- New hope for patients with end-stage liver disease - Jan 12, 2011
- Umbilical cord cells may be useful in arthritis treatment - Nov 16, 2010
- Pak businessman is Delhi's first marrow transplant case from unrelated donor - Sep 17, 2012
- Breast milk can be source for stem cells - Oct 18, 2011
- Breakthrough in leukemia treatment - Jan 18, 2010
- 'Lion King' musical star Shannon Tavares dies at age 11 - Nov 03, 2010
- Menstrual blood stem cells can treat many ailments - May 04, 2011
- Mums' stem cells could be key to treating genetic disease before birth - Jan 19, 2011
- Salman Khan to donate his bone marrow - Nov 14, 2010
- Mechanism that regulates movement of blood-forming stem cells in body identified - Mar 26, 2009
Tags: blood cancer, blood cancers, blood cells, bone marrow transplantation, bone marrow transplants, cancer centre, cord blood stem cells, efficiency and responsiveness, engraftment, enzyme inhibitor, enzyme technology, graft failure, md anderson cancer, morbidity and mortality, patient morbidity, rush university, stem cell transplantation, texas md anderson, transplant centres, university medical centre